KLRS
NASD Kalaris Therapeutics, Inc.$2.23 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.23, $0.07 below the day’s high of $2.30
- YTD change
- -73.58%
- vs 20-day SMA
- -22.69%
- vs 200-day SMA
- -62.09%
Price ranges
Price & Performance
-3.59 (-61.68%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 82.7% away from all-time highs of $12.90
- KLRS is down 74% since the beginning of the year
- KLRS is down 53% over the past 12 months
- KLRS is down 32% over the past 1 month
- 4% of all KLRS investors are betting against KLRS
KLRS reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -56.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -21.20%
- vs 8-day SMA
- -13.90%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
